Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib With or Without Cryoablation for Advanced Biliary Tract Cancer (CASTLE-ZS-04): a Multicenter, Randomized, Phase 2 Study

NCT07829874 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07829874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07829874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib With or Without Cryoablation for Advanced Biliary Tract Cancer (CASTLE-ZS-04): a Multicenter, Randomized, Phase 2 Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 20, 2026
Completion date
September 20, 2029
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc)